Literature DB >> 20104996

Non-animal approaches for consumer safety risk assessments: Unilever's scientific research programme.

Paul Carmichael1, Michael Davies, Matt Dent, Julia Fentem, Samantha Fletcher, Nicola Gilmour, Cameron MacKay, Gavin Maxwell, Leona Merolla, Camilla Pease, Fiona Reynolds, Carl Westmoreland.   

Abstract

Non-animal based approaches to risk assessment are now routinely used for assuring consumer safety for some endpoints (such as skin irritation) following considerable investment in developing and applying new methods over the past 20 years. Unilever's research programme into non-animal approaches for safety assessment is currently focused on the application of new technologies to risk assessments in the areas of skin allergy, cancer and general toxicity (including inhalation toxicity). In all of these areas, a long-term investment is essential to increase the scientific understanding of the underlying biological and chemical processes that we believe will ultimately form a sound basis for novel risk assessment approaches. Our research programme in these priority areas consists of in-house research as well as Unilever-sponsored academic research, involvement with EU-funded projects (e.g. Sens-it-iv, carcinoGENOMICS), participation in cross-industry collaborative research (e.g. COLIPA, EPAA) and ongoing involvement with other scientific initiatives on non-animal approaches to risk assessment (e.g. UK NC3Rs, US 'Human Toxicology Project' consortium). 2009 FRAME.

Entities:  

Mesh:

Year:  2009        PMID: 20104996     DOI: 10.1177/026119290903700605

Source DB:  PubMed          Journal:  Altern Lab Anim        ISSN: 0261-1929            Impact factor:   1.303


  5 in total

1.  Next Generation Risk Assessment of the Anti-Androgen Flutamide Including the Contribution of Its Active Metabolite Hydroxyflutamide.

Authors:  Tessa C A van Tongeren; Paul L Carmichael; Ivonne M C M Rietjens; Hequn Li
Journal:  Front Toxicol       Date:  2022-06-02

2.  Cell transformation assays for prediction of carcinogenic potential: state of the science and future research needs.

Authors:  Stuart Creton; Marilyn J Aardema; Paul L Carmichael; James S Harvey; Francis L Martin; Robert F Newbold; Michael R O'Donovan; Kamala Pant; Albrecht Poth; Ayako Sakai; Kiyoshi Sasaki; Andrew D Scott; Leonard M Schechtman; Rhine R Shen; Noriho Tanaka; Hemad Yasaei
Journal:  Mutagenesis       Date:  2011-08-17       Impact factor: 3.000

3.  An engineering approach to biomedical sciences: advanced testing methods and pharmacokinetic modeling.

Authors:  Gaetano Lamberti; Sara Cascone; Giuseppe Titomanlio
Journal:  Transl Med UniSa       Date:  2012-10-11

4.  A Next-Generation Risk Assessment Case Study for Coumarin in Cosmetic Products.

Authors:  Maria T Baltazar; Sophie Cable; Paul L Carmichael; Richard Cubberley; Tom Cull; Mona Delagrange; Matthew P Dent; Sarah Hatherell; Jade Houghton; Predrag Kukic; Hequn Li; Mi-Young Lee; Sophie Malcomber; Alistair M Middleton; Thomas E Moxon; Alexis V Nathanail; Beate Nicol; Ruth Pendlington; Georgia Reynolds; Joe Reynolds; Andrew White; Carl Westmoreland
Journal:  Toxicol Sci       Date:  2020-07-01       Impact factor: 4.849

5.  Latent Variables Capture Pathway-Level Points of Departure in High-Throughput Toxicogenomic Data.

Authors:  Danilo Basili; Joe Reynolds; Jade Houghton; Sophie Malcomber; Bryant Chambers; Mark Liddell; Iris Muller; Andrew White; Imran Shah; Logan J Everett; Alistair Middleton; Andreas Bender
Journal:  Chem Res Toxicol       Date:  2022-03-25       Impact factor: 3.973

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.